Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation

Rhea-AI Filing Summary

Dare Bioscience director Gregory W. Matz received a grant of 30,805 shares of common stock in the form of restricted stock units as compensation for serving on the company’s board and its committees. Each RSU converts into one share when it vests on January 4, 2027. After this award, he holds 30,847 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Matz Gregory W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common stock	30,805	$0.00	--

Holdings After Transaction: Common stock — 30,847 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 30,805 shares Shares after transaction: 30,847 shares Grant price per share: $0.0000 per share +1 more

4 metrics

RSU grant size 30,805 shares Restricted stock units granted as board compensation

Shares after transaction 30,847 shares Total common stock held directly after grant

Grant price per share $0.0000 per share Reported transaction price for RSU award

RSU vesting date January 4, 2027 Date when RSUs convert into common shares

Key Terms

restricted stock units ("RSU"), contingent right, in lieu of cash compensation, vests

4 terms

restricted stock units ("RSU") financial

"Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation"

contingent right financial

"Each RSU represents a contingent right to receive one share when vested"

in lieu of cash compensation financial

"RSU granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees"

vests financial

"The RSUs vests on January 4, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:21 PM Accepted by SEC EDGAR 07/02/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matz Gregory W

(Last) (First) (Middle)

3655 NOBEL DRIVE

SUITE 260

(Street)

SAN DIEGO CALIFORNIA 92122

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	06/30/2026		A		30,805(1)	A	$0	30,847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.

Remarks:

	/s/ Sabrina Martucci Johnson, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dare Bioscience (DARE) director Gregory W. Matz report?

Gregory W. Matz reported receiving 30,805 restricted stock units as compensation for serving on Dare Bioscience’s board and committees. These RSUs represent a grant of common stock, not an open-market purchase, and are structured as equity-based compensation.

How many Dare Bioscience (DARE) shares does Gregory W. Matz hold after this Form 4?

Following the reported grant, Gregory W. Matz holds 30,847 shares of Dare Bioscience common stock directly. This total reflects the addition of 30,805 restricted stock units awarded in lieu of cash compensation for his board and committee service.

Is the Dare Bioscience (DARE) Form 4 transaction an open-market buy or compensation grant?

The Form 4 shows a compensation grant, not an open-market purchase. The 30,805 shares are restricted stock units awarded in lieu of cash compensation for Gregory W. Matz’s service on Dare Bioscience’s board of directors and its committees.

When do Gregory W. Matz’s Dare Bioscience (DARE) RSUs vest?

The restricted stock units granted to Gregory W. Matz vest on January 4, 2027. Each RSU represents a contingent right to receive one Dare Bioscience common share upon vesting, aligning his compensation with the company’s future performance over time.

What does each RSU granted to Gregory W. Matz by Dare Bioscience (DARE) represent?

Each restricted stock unit represents a contingent right to receive one share of Dare Bioscience common stock when vested. The 30,805 RSUs granted in this Form 4 filing will convert into shares on their vesting date, subject to applicable award terms.